The role of certican (everolimus, rad) in the many pathways of chronic rejection
- 1 November 2001
- journal article
- research article
- Published by Elsevier in Transplantation Proceedings
- Vol. 33 (7-8) , 3215-3220
- https://doi.org/10.1016/s0041-1345(01)02369-7
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RADThe Annals of Thoracic Surgery, 2000
- ORAL EFFICACY OF THE MACROLIDE IMMUNOSUPPRESSANT SDZ RAD AND OF CYCLOSPORINE MICROEMULSION IN CYNOMOLGUS MONKEY KIDNEY ALLOTRANSPLANTATIONTransplantation, 2000
- COMBINED IMMUNOSUPPRESSION WITH CYCLOSPORINE (NEORAL) AND SDZ RAD IN NON-HUMAN PRIMATE LUNG TRANSPLANTATION: SYSTEMATIC PHARMACOKINETIC-BASED TRIALS TO IMPROVE EFFICACY AND TOLERABILITY 1Transplantation, 2000
- Chronic allograft nephropathy: An updateKidney International, 1999
- COADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTSTransplantation, 1999
- Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporineThe Journal of Heart and Lung Transplantation, 1999
- The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferationTransplantation Proceedings, 1998
- The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantationTransplantation Proceedings, 1998
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997